SOPHiA Genetics SA opened lower at $7.31, compared with its previous close of $7.47. In the last trading session, the stock traded between $7.22 and $7.96. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in SOPHiA Genetics SA is now worth
$ 50.54
Resulting in a loss of
$ 49.46 (49.46%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.40 (+5.41%)
Day High
$7.96
Day Low
$7.22
Day Open
$7.31
Prev Close
$7.47
Volume
6,84,413
1W Return
12.64%
1M Return
9.09%
3M Return
3.42%
6M Return
64.28%
1Y Return
70.32%
Fundamentals
Market Cap ($ Mn)
670
PE Ratio
-
PB Ratio
8.33
PEG Ratio
-
ROE
-107.74%
ROCE
-59.52%
EPS (TTM)
$-0.24
Investment Returns
1 Week
12.64%
1 Month
9.09%
3 Months
3.42%
6 Months
64.28%
9 Months
64.62%
Financials
Quarterly
All values in $ Mn
18.3
Jun 25
19.5
Sep 25
21.7
Dec 25
21.7
Mar 26
23.3
Jun 26
24.3
Sep 26
Updates
3Nov
Sophia Genetics raises FY26 sales guidance to $96 million
Sophia Genetics raised FY2026 sales guidance to $96.000 million. New guidance beats analyst consensus estimate of $95.252 million. Guidance narrowed from previous range of $94.000 million-$96.000 million. Q3 revenue of $24.267 million beat estimates by 0.97%. Q3 EPS loss of $0.24 missed consensus estimate of $0.18.
9 days ago
4Aug
Sophia Genetics Q2 Results: Sales Rise 27.22% YoY to $23.310M
Sophia Genetics delivered strong top-line growth in Q2 with sales of $23.310M, up 27.22% YoY and beating estimates. However, EPS of $(0.30) missed the $(0.20) estimate, reflecting margin pressures despite a 9.09% improvement in losses compared to the prior year.
3mo ago
4Aug
Sophia Genetics raises FY26 sales guidance to $94-96M
Sophia Genetics increases FY2026 sales guidance to $94.000M-$96.000M, beating the $93.403M estimate. The previous range was $92.000M-$94.000M.
3mo ago
4Aug
SOPHiA GENETICS signs AstraZeneca deal for two companion diagnostics
SOPHiA GENETICS announced a global collaboration with AstraZeneca on Aug. 4, 2026, to develop two companion diagnostics. The partnership involves converting Solid Tumor and Hematological Oncology applications into decentralized CDx programs, aiming to standardize biomarker detection and accelerate patient access to precision oncology therapies worldwide.
3mo ago
20Jul
HC Wainwright initiates coverage on Sophia Genetics with Buy rating
HC Wainwright & Co. analyst Swayampakula Ramakanth has initiated coverage on Sophia Genetics with a Buy rating and a price target of $12.
3mo ago
22Jun
SOPHiA GENETICS appoints new CEO as shareholders approve all proposals
SOPHiA GENETICS shareholders approved all proposals at the 2026 AGM, electing Dr. Jurgi Camblong as Executive Chairman and Ross Muken as CEO effective July 1, 2026. The meeting also re-elected six directors, approved compensation plans, and ratified financial reports for 2025. Governance updates included the introduction of a Lead Independent Director role.
